China (Mainland)
Premiumsupplier
Treatment of Breast Cancer 98% Fulvestrantly Powder Anti Estrogen API In Stock Fast Delivery CAS NO.129453-61-8
- Min.Order: 1 Gram
- Payment Terms: T/T,
- Product Details
Keywords
- Fulvestrantly
- Fulvestrantly
- Fulvestrantly
Quick Details
- ProName: Treatment of Breast Cancer 98% Fulvest...
- CasNo: 129453-61-8
- Molecular Formula: C32H47F5O3S
- Appearance: white powder
- Application: A novel steroidal estrogen antagonist ...
- DeliveryTime: immediately
- PackAge: aluminum foil bag
- Port: HK, Shanghai, Shenzhen
- ProductionCapacity: 100 Kilogram/Month
- Purity: 99%
- Storage: cool and dry place
- Transportation: EMS,DHL,HK post,EUB,ETK,NL post,German...
- LimitNum: 1 Gram
Superiority
1.High Quality:
Quality is life. Quality is the most important element for all goods. We have a lab doing research in Wuhan China and produce sarms in bulk quantity. We have 8 years experience making all kinds of sarms. And all our old customers throughout the world have very positive feedbacks towards our sarms. Purity is all guaranteed over 98%. HPLC and NMR is available if needed.
2.Reasonable price:
We provide high quality products with competitive price in China. All customers are welcomed to send us inquiries and get quotation.
3.Low MOQ:
No worry about the low MOQ, our MOQ is 1 gram or even lower.
4.Good Service.
Fast response. We promise to reply within 24 hours including holidays and send quotation sheet and other documents within 48 hours.
Before making orders, we do not cheat customers in order to get orders.
After selling, we promise to be reponsible and so not disappear if there is any complaint from customers on either our products or services.
5. Fast shipping and secure courier.
We promise to send out products and provide tracking number within 3 working days. And we send via different couriers based on different destination countries. We usually use NL post, HK post, Germany post, EUB, ETK, etc.
6.About resending or refunding if there is any loss of packages or failure to getting through custom.
We promise to resend up to half if it happens unluckily.
Details
Basic Info
MF: C32H47F5O3S
MW: 606.77
mp 104-106°C
storage temp. 2-8°C
Chemical Properties White Powder
Usage A novel steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).
Usage Antiestrogen
Biological Activity A high affinity estrogen receptor antagonist (IC 50 = 0.29 nM), devoid of any partial agonism both in vitro and in vivo . Also high affinity agonist at the membrane estrogen receptor GPR30.
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Nuclear Receptors;Chiral Reagents;Steroids;Sulfur & Selenium Compounds;FASLODEX;Anti-cancer&immunity
Synonyms: ICI 182,780;;-13C1-D2;FASLODEX;(7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;7A,17B-[9[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL;(7alpha,17beta)-nonyl);estra-1,3,5(10)-triene-3,17-diol,7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)
Description:
Fulvestrant Acetate (trade name Faslodex, by Astra Zeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is a completeestrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.
Applications:
Fulvestrant Acetate is a selective estrogen receptor degrader (SERD). It is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
Fulvestrant Acetate provides effective second-line therapy in metastatic or locally advanced breast cancer for postmenopausal women who relapse or progress after previous endocrine therapy.
Four clinical trials in this setting showed similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.
A Phase 2 clinical trial, sponsored by Atossa Genetics, is being conducted by Dr. Sheldon Feldman, President of the The American Society of Breast Surgeons, at Columbia University Breast Center in New York City on the use of Fulvestrant Acetate administered through the microcatheter into the lactiferous duct as neoadjuvant treatment forductal carcinoma in situ and invasive breast cancer.
Description:
Fulvestrant Acetate (trade name Faslodex, by Astra Zeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is a completeestrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.
Applications:
Fulvestrant Acetate is a selective estrogen receptor degrader (SERD). It is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy.
Fulvestrant Acetate provides effective second-line therapy in metastatic or locally advanced breast cancer for postmenopausal women who relapse or progress after previous endocrine therapy.
Four clinical trials in this setting showed similar efficacy to the other hormonal agents (aromatase inhibitors and tamoxifen) with good tolerability profile. Fulvestrant had a lower incidence of joint disorders.
A Phase 2 clinical trial, sponsored by Atossa Genetics, is being conducted by Dr. Sheldon Feldman, President of the The American Society of Breast Surgeons, at Columbia University Breast Center in New York City on the use of Fulvestrant Acetate administered through the microcatheter into the lactiferous duct as neoadjuvant treatment forductal carcinoma in situ and invasive breast cancer.
Packing and shipping
